The Motor Neurone Disease Genetics and Therapeutics Research Group, led by Professor Anthony Akkari, aims to identify genetic mechanisms and mutations in neurological conditions, particularly motor neurone diseases. Our focus is to translate this research into developing personalised treatments. We work closely with Professors Steve Wilton and Sue Fletcher towards this goal.
Through Professor Akkari’s background in pharmacogenetics, Perron Institute’s MND research approach is distinct and unique to other efforts around the world. Our team have successfully created a comprehensive pipeline of targeted therapeutics for MND, we expect shortly we will have phase one ready targeted MND therapy for a small group of patients with SOD1 mutations and sporadic ALS.
- Wilton, Akkari, Flynn, Pitout & Fletcher. FightMND Drug Development Grant for "Pre-clinical development of a SOD1 genetic therapy in sporadic ALS: enabling investigational new drug submission" (2021-2023)
- Turner, Flynn, Akkari, Pitout, Barton & Wilton. MND Research Institute of Australia, Innovator Grant Scheme for "Development of a novel splice-switching molecular therapy for MND" (2020-2021)
- Anderton, Meloni, Akkari & Chiba-Falek. Raine Medical Research Foundation Priming Grant for "Investigating a novel class of peptide as a therapeutic for neurodegenerative disorders" (2020-2021)
- Kôks, Aoun & Akkari. MSWA for “Trajectories of Outcomes in Neurological Conditions study – TONiC in WA” (2019-2022)
- MSWA Genomic Medicine Grant
- Akkari, Flynn, Pitout. Giumelli Foundation Grant for "Establishing an MND cell model laboratory" (2019-2021)